Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
NEOPHARM, Inc. Signs Exclusive License Agreement for the Use of CINTREDEKIN BESUDOTOX (IL13-PE38QQR) for the Treatment of Pulmonary Fibrosis and Asthma
June 27th, 2007
NEOPHARM, Inc. (NASDAQ:NEOL), announced that it has entered into an exclusive patent license agreement with the National Institutes of Health (NIH) for the development of CINTREDEKIN BESUDOTOX, or IL13-PE38QQR, for the treatment of Pulmonary Fibrosis and asthma. There are many forms of Pulmonary Fibrosis (PF), one of them, Idiopathic Pulmonary Fibrosis (IPF) also known as Usual Interstitial Pneumonia (UIP), is a progressive disorder affecting approximately 200,000 Americans and over five million people worldwide. With very few treatments currently available for this disease and no known cure, there exists a significant unmet medical need for new therapy options for...
Source: Medical Patent Law Weekly (2007-06-27)
|
